Algernon Pharmaceuticals Inc.

AGN on CSEToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.20CAN -0.01/-4.76%45,0000.10 / 0.559.47 M
BTHCF on OTCQBToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.16US -0.00/-1.77%11,5880.07 / 0.407.51 M

Contact Information

Algernon Pharmaceuticals Inc.

Headquarters:
700 West Pender Street, Suite 915
Vancouver, British Columbia
Canada, V6C 1G8
Tel: 604-646-1553
Email: Send a message
Website: Visit website
For more information...
Lead: Barry Mire

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).

Christoper J. Moreau - Chief Executive Officer

Mark Williams, PhD, MBA - Chief Science Officer

Michael Sadhra, CA - Chief Financial Officer & Director

Raj Attariwala, MD, PhD. - Director

Michael Sadhra, CA - Chief Financial Officer & Director

David Levina - Director

Stock Information

Company Overview

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).

Management

Christoper J. Moreau - Chief Executive Officer

Mark Williams, PhD, MBA - Chief Science Officer

Michael Sadhra, CA - Chief Financial Officer & Director

Board of Directors

Raj Attariwala, MD, PhD. - Director

Michael Sadhra, CA - Chief Financial Officer & Director

David Levina - Director

Contact Information

Headquarters:
700 West Pender Street, Suite 915
Vancouver, British Columbia
V6C 1G8, Canada
Telephone: 604-646-1553
Email: Send a message
Website: Visit website